First Eagle Investment Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

First Eagle Investment Management’s Portfolio CASC Stock Details CASC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-24,999	Closed	-$108K	–	343
2016 Q4	$108K	Sell	24,999 -41,668	-63%	-$269K	﹤0.01%	264
2016 Q3	$656K	Hold	66,667	–	–	﹤0.01%	253
2016 Q2	$377K	Buy	66,667 +16,667	+33%	+$113K	﹤0.01%	276
2016 Q1	$381K	Hold	50,000	–	–	﹤0.01%	265
2015 Q4	$666K	Buy	+50,000	New	+$861K	﹤0.01%	238
2015 Q2	–	Sell	-216,667	Closed	-$2.12M	–	335
2015 Q1	$2.12M	Buy	+216,667	New	+$2.12M	0.01%	206
2014 Q3	–	Sell	-397,340	Closed	-$7.72M	–	356
2014 Q2	$7.72M	Sell	397,340 -56,825	-13%	-$1M	0.02%	179
2014 Q1	$8.15M	Buy	454,165 +16,667	+4%	+$274K	0.02%	147
2013 Q4	$4.62M	Buy	437,498 +58,283	+15%	+$652K	0.01%	171
2013 Q3	$4.69M	Buy	379,215 +163,298	+76%	+$1.72M	0.01%	182
2013 Q2	$2.02M	Buy	+215,917	New	+$2.77M	0.01%	225

Other funds holding CASC

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

First Eagle Investment Management's CASC Position: Q1 2017 in Review

First Eagle Investment Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2017, closing a stake of 24,999 shares — an estimated $108K sold.

First Eagle Investment Management first reported a position in CASC in Q2 2013 and held it in 11 quarters. The position peaked at $8.15M in Q1 2014. 78 funds tracked by Wall St. Rank hold CASC as of Q1 2017.

First Eagle Investment Management reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
First Eagle Investment Management sold 24,999 Cascadian Therapeutics, Inc. shares in Q1 2017, an estimated $108K.
First Eagle Investment Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 11 quarters.
First Eagle Investment Management's Cascadian Therapeutics, Inc. position peaked at $8.15M in Q1 2014.
78 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2017.

Based on First Eagle Investment Management's 13F filing for Q1 2017, filed 5 May 2017.